J&J Says Acquired Eye Drug Uses Smaller Antibody Format
OLN324, a retinal drug J&J is acquiring from Ollin Biosciences, uses a minibody format designed to improve control of retinal fluid. J&J said the format and the drug’s angiopoietin-2 potency could allow longer intervals between treatments for wet AMD patients.